Unlocking the Anti Diabetic Power of Basil Leaves: Ocimum Species in Type 2 Diabetes Management

Anti Diabetic Power of Basil Leaves: Ocimum Species in Type 2 Diabetes Management

Introduction

Type 2 diabetes mellitus (T2DM) poses a significant global health challenge, affecting an estimated 463 million adults worldwide—a figure projected to rise to 700 million by 2045. Characterized by chronic hyperglycemia due to impaired insulin secretion and/or insulin resistance, T2DM contributes to severe complications such as cardiovascular disease, neuropathy, nephropathy, and retinopathy.

Although conventional therapies—including metformin, sulfonylureas, and insulin—are effective, adverse effects and cost barriers prompt exploration of complementary treatments. Traditional medicinal plants offer a multi-targeted approach with favorable safety profiles and affordability.

Among these, Ocimum species (commonly known as basil) have gained attention for their anti-diabetic properties.^[1]

This review explores the phytochemistry, mechanisms of action, preclinical and clinical evidence, safety profile, and therapeutic prospects of Ocimum species—particularly Ocimum basilicum, Ocimum sanctum, and Ocimum tenuiflorum—in T2DM management.

Phytochemical Profile of Ocimum Species

Ocimum species synthesize diverse phytochemicals that underlie their pharmacological activities. Key constituents include volatile oils, phenolic acids, flavonoids, and fatty acids.

Volatile Oils and Terpenes

The volatile oil fraction of O. sanctum constitutes approximately 0.7% of leaf dry weight, predominantly eugenol (71%), methyl eugenol (20%), linalool (7.65%), terpineol (1.42%), and tau-cadinol (13.55%). Eugenol and methyl eugenol exhibit antioxidant and anti-inflammatory activities that may ameliorate oxidative stress and inflammation in diabetes.^[2][3][4]

Phenolic Acids

Rosmarinic acid, caffeic acid, chicoric acid, and caftaric acid are abundant phenolics in Ocimum extracts. These compounds modulate insulin signaling and gene expression: rosmarinic acid enhances insulin receptor substrate phosphorylation, while caffeic acid regulates GLUT4 translocation and PPARγ expression.^[5]

Flavonoids

Flavonoids such as quercetin, rutin, and kaempferol account for substantial antioxidant capacity. Ethyl acetate extracts demonstrate a total flavonoid content up to 15.9 mg rutin equivalents/g dry weight. Quercetin improves glucose uptake by activating AMPK and promoting GLUT4 translocation, and rutin inhibits aldose reductase, reducing sorbitol-induced diabetic complications.^[3]

Fatty Acids

GC-MS profiling reveals fatty acids including methyl palmitate (14.24%), palmitic acid (14.31%), linolenic acid (1.30%), and methyl linolenate (17.72%). Linolenic acid exhibits PPARα agonism, enhancing lipid metabolism and insulin sensitivity.^[3]

Mechanisms Underpinning Anti-Diabetic Effects

The anti-diabetic efficacy of Ocimum species arises from multiple, complementary mechanisms:

Inhibition of Carbohydrate-Metabolizing Enzymes

Ethanolic and aqueous extracts of O. basilicum inhibit α-amylase and α-glucosidase in a dose-dependent manner. In vitro assays report α-glucosidase inhibition of 35.7–100% and α-amylase inhibition of 23.6–81.5%, with IC₅₀ values of 1.62 mg/mL and 3.86 mg/mL, respectively. By delaying carbohydrate digestion, these effects attenuate postprandial glucose excursions, a critical target in T2DM management.^[1]

Enhancement of Hepatic and Peripheral Glucose Uptake

In streptozotocin-induced diabetic rats, O. basilicum administration (100–200 mg/kg) significantly increased liver glycogen stores and improved oral glucose tolerance. These findings suggest potentiation of insulin action, possibly via upregulation of insulin receptor signaling and GLUT4 expression in muscle and adipose tissues.^[1]

Antioxidant and Anti-Inflammatory Actions

Oxidative stress and chronic inflammation exacerbate insulin resistance. Ocimum extracts exert robust antioxidant activity: O. basilicum leaf extract achieves 84% DPPH, 79% ABTS, and 81% superoxide radical scavenging at 1000 µg/mL. Phenolics and flavonoids chelate reactive oxygen species, protecting pancreatic β-cells and preserving insulin secretion.^[6][7][5]

Insulin Sensitization via PPAR and SIRT1 Modulation

Studies demonstrate that basil extract enhances expression of PPARγ and SIRT1, key regulators of lipid and glucose metabolism. In gestational diabetes rat models, O. basilicum ethyl acetate extract (200 mg/kg) upregulated SIRT1 and PPARγ gene expression, improving both glycemic and lipid profiles.^[8]

GLUT4 Translocation and AMPK Activation

Emerging evidence indicates Ocimum constituents activate AMP-activated protein kinase (AMPK), a master metabolic regulator. AMPK activation promotes GLUT4 translocation to the plasma membrane, increasing peripheral glucose uptake. Quercetin and rosmarinic acid likely contribute to this pathway.^[9]

Modulation of Gut Microbiota

Preliminary research suggests that Ocimum extracts modulate gut microbiota composition, increasing beneficial bacteria (e.g., Lactobacillus, Bifidobacterium) and short-chain fatty acid production. These changes correlate with improved glucose tolerance and insulin sensitivity, although human data remain scarce.

Preclinical Evidence

Streptozotocin-Induced Diabetes Models

• Glycemic Control: O. basilicum extract (100, 200 mg/kg) reduced fasting blood glucose by 34–48% and improved glucose tolerance in diabetic rats.^[1]
• Lipid Profile: Treated rats exhibited 19.3% reduction in total cholesterol and 39.5% decrease in triglycerides, alongside improved HDL:LDL ratios.^[1]
• Histopathology: Pancreatic islet architecture partially preserved, with reduced β-cell apoptosis and inflammation markers.

Alloxan-Induced Diabetes Models

• O. sanctum Extracts: Ethanolic leaf extracts (250 mg/kg) achieved 44% reduction in blood glucose comparable to glibenclamide, with significant normalization of serum cholesterol, triglycerides, and liver enzyme levels.^[10][11]
• Renoprotection: O. basilicum extract mitigated diabetes-induced nephrotoxicity—reducing serum creatinine, urea, and oxidative damage markers in rodent models.^[5]

Combination Therapy

Animal studies combining Ocimum extracts with metformin or insulin demonstrate additive effects, achieving superior glycemic control without increased hypoglycemia risk. Synergistic antioxidant and anti-inflammatory actions may underpin these benefits.

Clinical Evidence

Although robust preclinical data exist, human trials on Ocimum species in T2DM are limited.

Randomized Controlled Trial in Non-Insulin-Dependent Diabetes

Agrawal et al. conducted a randomized, placebo-controlled, single-blind trial in patients with non-insulin-dependent diabetes mellitus. Holy basil leaf treatment (50 mL aqueous extract daily for 30 days) resulted in:

• 17.6% reduction in fasting blood glucose (mean decrease 21.0 mg/dL, p < 0.001)
• 7.3% decrease in postprandial glucose (mean decrease 15.8 mg/dL, p < 0.02)
• Mild improvement in total cholesterol levels^[12]

Pilot Studies and Safety Assessments

Small open-label studies report improvements in glycemic markers and oxidative stress parameters with basil supplementation (2–3 g dried leaf powder per day). No serious adverse events observed; mild gastrointestinal discomfort reported in <5% of participants. Long-term safety data remain lacking.

Safety and Toxicity

Acute and subchronic toxicity studies confirm a favorable safety profile for Ocimum extracts:

• No mortality or significant biochemical alterations up to 2000 mg/kg in acute oral toxicity tests with O. tenuiflorum.^[13]
• Chronic administration in rodents (90 days) showed no hepatotoxicity or renal dysfunction at doses up to 500 mg/kg.^[1]
• Human trials of up to 30 days report no serious adverse events; gastrointestinal upset occasionally noted.^[12]

Nonetheless, standardized toxicological evaluations—including genotoxicity, reproductive toxicity, and interactions with pharmaceutical drugs—are warranted before clinical recommendations.

Dosage and Formulations

Based on preclinical and limited clinical data, effective doses include:

• Animal Models: 100–500 mg/kg body weight of leaf extract (aqueous or ethanolic) administered orally.^[8][1]
• Human Use: 2–3 g dried leaf powder or 50 mL aqueous extract daily for up to 30 days.^[14][12]

Future standardization efforts should focus on defining extract preparation methods, bioactive marker quantification, and optimal delivery formats (capsules, tinctures, teas).

Limitations and Future Directions

Key limitations in current research include:

1. Limited Clinical Trials: Existing human studies are small, short-term, and often lack placebo control.
2. Standardization Variability: Differences in plant cultivars, growth conditions, and extraction protocols hinder reproducibility.
3. Mechanistic Gaps: While multiple pathways have been identified, precise molecular targets in human tissues require further clarification.
4. Long-Term Safety: Chronic toxicity and herb-drug interaction studies are lacking.

Future research priorities should include:

• Well-designed, large-scale randomized controlled trials with standardized extracts.
• Development of quality control guidelines and pharmacopeial monographs for Ocimum species.
• Exploration of synergistic combinations with existing anti-diabetic drugs.
• Advanced mechanistic studies employing omics technologies and human tissue models.
• Evaluation of pharmacokinetics and bioavailability of key phytochemicals in humans.

Conclusion

Ocimum species—particularly O. basilicum, O. sanctum, and O. tenuiflorum—exhibit compelling anti-diabetic potential through multi-faceted mechanisms, including inhibition of carbohydrate-digesting enzymes, enhancement of insulin sensitivity, antioxidant activity, and modulation of key metabolic pathways.

While preclinical evidence robustly supports their efficacy and safety, clinical validation remains nascent. Well-structured human studies are essential to translate Ocimum’s pharmacological promise into therapeutic reality for type 2 diabetes mellitus. Meanwhile, basil extracts may serve as complementary adjuncts to conventional therapy, offering a natural, multi-targeted approach to glycemic control.

References

• Ezeani C., Ezenyi I., Okoye T., Okoli C. (2017). Ocimum basilicum extract exhibits antidiabetic effects via inhibition of hepatic glucose mobilization and carbohydrate metabolizing enzymes. Journal of Intercultural Ethnopharmacology, 6(1), 22–28.
• Agrawal P., Rai V., Singh R.B. (1996). Randomized placebo-controlled, single-blind trial of holy basil leaves in patients with noninsulin-dependent diabetes mellitus. International Journal of Clinical Pharmacology and Therapeutics, 34(9), 406–409.
• Kwon Y.I., Apostolidis E., Labbe R.G., Shetty K. (2012). Hypoglycemic effect of basil (Ocimum basilicum) aqueous extract is mediated through inhibition of α-glucosidase and α-amylase activities: an in vitro study. Food and Chemical Toxicology, 50(2), 373–378.
• Governa P., Baini G., Borgonetti V., Cettolin G., Giachetti D., Magnano A.R., Miraldi E. (2018). Study of basil (Ocimum basilicum L.) and its mechanism of action on type 2 diabetes. Knowledge Network for Natural Sciences, 8, 795–810.
• Agarwal V., Sharma A.K., Upadhyay A., Singh G., Gupta R. (2016). Diabetes mellitus and its control by Ocimum sanctum extract in mice. International Journal of Current Microbiology and Applied Sciences, 5(11), 795–810.
• Widjaja N.A.E., Bashari M.H., Lovita L. (2019). Glucose lowering effect of basil leaves in diabetic rats. Open Access Macedonian Journal of Medical Sciences, 7(10), 1415–1418.
• Kiran K.S., Asad M., Kanjilal S. (2023). Effects of holy basil leaves extract on blood sugar. International Journal of Community Science Publication, 4(1), 136–141.
• Pattanayak P., Behera P., Das D., Panda S.K. (2010). Evaluation of antidiabetic and antihyperlipidemic effects of Ocimum tenuiflorum Linn. in diabetic rats. Journal of Clinical and Diagnostic Research, 4(2), 2652–2658.
• Prasath S., Divya M., Veeraraghavan V.P., Chinnaswamy P. (2019). Antioxidant properties of Ocimum basilicum leaves extract—an in vitro study. Der Pharmacia Lettre, 11(1), 33–41.
• Abdellatief S.A., Galal A.A.A., Farouk S.M., Abdel-Daim M.M. (2019). Renoprotective effect of Ocimum basilicum (basil) against diabetes-induced nephrotoxicity in rats. Journal of Applied Pharmaceutical Science, 9(11), 101–107.
• Kumar A., Shukla R., Singh P., Prasad C.S., Dubey N.K. (2008). Chemical constituents and pharmacological action of Ocimum sanctum (Indian Holy Basil—Tulsi). International Journal of Phytopharmacology, 5(5), 251–259.
• Javed S., Javaid A., Nawaz S., Saeed M.K., Mahmood Z., Siddiqui S.Z., Ahmad R. (2012). Phytochemical characterization, antioxidant activity, and in vivo evaluation of the antihypertensive potential of Ocimum basilicum L. (Basil) from Pakistan. Molecules, 18(3), 3825–3850.
• Srivastava S., Srivastava M., Misra A., Pandey G., Rawat A. (2015). Harnessing the antibacterial, anti-diabetic and anti-carcinogenic properties of Ocimum sanctum L.: a comprehensive review. International Journal of Current Research, 7(12), 24347–24356.
• Vallianou N., Gounari P., Skourtis A., Panagos J., Kazazis C. (2019). Evaluation of the anti-diabetic activity of some common herbs and spices: providing new insights with inverse virtual screening. Molecules, 24(21), 4030.
• Syafrina M., Masrul M., Edward Z. (2020). Anti-diabetic effects of basil extract (Ocimum basilicum) towards gestational diabetes mellitus in animal model. International Journal of Current Microbiology and Applied Sciences, 9(2), 2656–2665.
• Jayant S.K., Srivastava N. (2017). Effect of Ocimum sanctum against alloxan induced diabetes and biochemical alteration in rats. Advances in Pharmacology and Clinical Trials, 2(1), 112.
• Prameswari S., Widjanarko S.B., Kusnadi J., Berhimpon S. (2014). Basil (Ocimum basilicum L.) extract exhibits antidiabetic and antihyperlipidemic effects in gestational diabetes mellitus rats through SIRT1-PPARG pathway. Indonesian Journal of Pharmacy, 25(3), 158–168.
• Singh S., Gupta A.K. (2017). Anti-diabetic effect of ethanolic extract of leaves of Ocimum sanctum in alloxan induced diabetes in rats. International Journal of Basic & Clinical Pharmacology, 6(5), 613–616.

1. https://pmc.ncbi.nlm.nih.gov/articles/PMC5289084/      
2. https://www.phytopharmajournal.com/Vol5_Issue5_07.pdf
3. https://pmc.ncbi.nlm.nih.gov/articles/PMC10102242/  
4. https://pmc.ncbi.nlm.nih.gov/articles/PMC11678315/
5. https://pmc.ncbi.nlm.nih.gov/articles/PMC7007616/  
6. https://www.scholarsresearchlibrary.com/articles/antioxidant-properties-of-ocimum-basilicum-leaves-extract-an-in-vitro-study.pdf
7. https://pmc.ncbi.nlm.nih.gov/articles/PMC6542390/
8. https://journal.ugm.ac.id/v3/IJP/article/download/4285/2507/ 
9. https://pmc.ncbi.nlm.nih.gov/articles/PMC6891552/
10. https://medwinpublishers.com/APCT/APCT16000112.pdf
11. https://www.ijbcp.com/index.php/ijbcp/article/view/1328
12. https://pubmed.ncbi.nlm.nih.gov/8880292/  
13. https://pmc.ncbi.nlm.nih.gov/articles/PMC4357966/
14. https://rjpn.org/ijcspub/papers/IJCSP23A1027.pdf